» Articles » PMID: 21737855

Cardiac Geometry in Children Receiving Chronic Peritoneal Dialysis: Findings from the International Pediatric Peritoneal Dialysis Network (IPPN) Registry

Abstract

Background And Objectives: Left ventricular hypertrophy (LVH) is an independent risk factor and an intermediate end point of dialysis-associated cardiovascular comorbidity. We utilized a global pediatric registry to assess the prevalence, incidence, and predictors of LVH as well as its evolution in the longitudinal follow-up in dialyzed children.

Design, Setting, Participants, & Measurements: Cross-sectional echocardiographic, clinical, and biochemical data were evaluated in 507 children on peritoneal dialysis (PD), and longitudinal data were evaluated in 128 patients. The 95(th) percentile of LV mass index relative to height age was used to define LVH.

Results: The overall LVH prevalence was 48.1%. In the prospective analysis, the incidence of LVH developing de novo in patients with normal baseline LV mass was 29%, and the incidence of regression from LVH to normal LV mass 40% per year on PD. Transformation to and regression from concentric LV geometry occurred in 36% and 28% of the patients, respectively. Hypertension, high body mass index, use of continuous ambulatory peritoneal dialysis, renal disease other than hypo/dysplasia, and hyperparathyroidism were identified as independent predictors of LVH. The use of renin-angiotensin system (RAS) antagonists and high total fluid output (sum of urine and ultrafiltration) were protective from concentric geometry. The risk of LVH at 1 year was increased by higher systolic BP standard deviation score and reduced in children with renal hypo/dysplasia.

Conclusions: Using height-adjusted left ventricular mass index reference data, LVH is highly prevalent but less common than previously diagnosed in children on PD. Renal hypo/dysplasia is protective from LVH, likely because of lower BP and polyuria. Hypertension, fluid overload, and hyperparathyroidism are modifiable determinants of LVH.

Citing Articles

Prospective Study of Modifiable Risk Factors of Arterial Hypertension and Left Ventricular Hypertrophy in Pediatric Patients on Hemodialysis.

Borzych-Duzalka D, Shroff R, Ranchin B, Zhai Y, Paglialonga F, Kari J Kidney Int Rep. 2024; 9(6):1694-1704.

PMID: 38899176 PMC: 11184401. DOI: 10.1016/j.ekir.2024.03.016.


Metabolic syndrome as risk factor for left ventricular hypertrophy in children with chronic kidney disease.

Drozdz M, Moczulska A, Rudzinski A, Drozdz D Front Endocrinol (Lausanne). 2023; 14:1215527.

PMID: 37324258 PMC: 10264689. DOI: 10.3389/fendo.2023.1215527.


Sodium handling in pediatric patients on maintenance dialysis.

Paglialonga F, Peter Schmitt C Pediatr Nephrol. 2023; 38(12):3909-3921.

PMID: 37148342 DOI: 10.1007/s00467-023-05999-7.


Left ventricular hypertrophy in pediatric patients on maintenance dialysis: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).

Merrill K, Galbiati S, Mitsnefes M Pediatr Nephrol. 2022; 38(6):1925-1933.

PMID: 36357637 DOI: 10.1007/s00467-022-05796-8.


Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease-A Pediatric Perspective.

Grund A, Sinha M, Haffner D, Leifheit-Nestler M Front Pediatr. 2021; 9:702719.

PMID: 34422725 PMC: 8372151. DOI: 10.3389/fped.2021.702719.


References
1.
Parekh R, Carroll C, Wolfe R, Port F . Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 2002; 141(2):191-7. DOI: 10.1067/mpd.2002.125910. View

2.
. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(2 Suppl 4th Report):555-76. View

3.
Schluter K, Piper H . Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol. 1992; 263(6 Pt 2):H1739-46. DOI: 10.1152/ajpheart.1992.263.6.H1739. View

4.
Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F . Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 1999; 50(3):321-8. DOI: 10.1046/j.1365-2265.1999.00651.x. View

5.
Stawowy P, Margeta C, Blaschke F, Lindschau C, Spencer-Hansch C, Leitges M . Protein kinase C epsilon mediates angiotensin II-induced activation of beta1-integrins in cardiac fibroblasts. Cardiovasc Res. 2005; 67(1):50-9. DOI: 10.1016/j.cardiores.2005.03.002. View